	e: 2021-10-23 r Name: Xu Ran			
Mar	uscript Title:_ <u>Identification</u>	on of ubiquitinated substra	te proteins and their gene expression patterns in lung	
	nocarcinoma_ luscript number (if known)	<u>.</u>	<u> </u>	
In the total part to the total total total total total total to the total tota	ne interest of transparency ne content of your manusc ies whose interests may b	, we ask you to disclose all ript. "Related" means any e affected by the content o necessarily indicate a bias	relationships/activities/interests listed below that are relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a relationship	t
<u>mar</u> The	nuscript only. author's relationships/act	ivities/interests should be	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript perta	
med	dication, even if that medic	cation is not mentioned in t	•	
	time frame for disclosure i		d in this manuscript without time limit. For all other it	ems,
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)	
		none (add rows as	institution,	
		needed)		
1		Time frame: Since the initia	planning of the work	
1	All support for the present manuscript (e.g., funding,	None		
	provision of study			
	materials, medical writing,			
	article processing charges,			
-	article processing charges, etc.)			
<u>-</u>	article processing charges,			
	article processing charges, etc.)			
-	article processing charges, etc.)			
2	article processing charges, etc.) No time limit for this item.	Time frame: past	36 months	
2	article processing charges, etc.) No time limit for this item. Grants or contracts from	Time frame: past ✓ None	36 months	
2	article processing charges, etc.) No time limit for this item.		36 months	
2	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated		36 months	
	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√None	36 months	
	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	✓ None ✓None	36 months	
3	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	✓ None ✓None	36 months	
3	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses Consulting fees	✓ None ✓None ✓None	36 months	
3	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	✓ None ✓None	36 months	

manuscript writing or

	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11		vNone	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
	ase summarize the above on the summarize the above of the summarize the summarize the above of the summarize t	onflict of interest in the following box:	

<u>Dat</u>	e: 2021-10-23			
	r Name:_Lu Tong			_
Mar	nuscript Title:_ <u>Identification</u>	on of ubiquitinated substrat	e proteins and their gene expression patterns in lung	-
	nocarcinoma		<u></u>	
	nuscript number (if known)			
to t	ne content of your manusc	ript. "Related" means any r	relationships/activities/interests listed below that are relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment	
			. If you are in doubt about whether to list a relationshi	
	vity/interest, it is preferable			i (P)
	following questions apply nuscript only.	to the author's relationship	ps/activities/interests as they relate to the <u>current</u>	
The	author's relationships/act	ivities/interests should be	<u>defined broadly</u> . For example, if your manuscript pert	ains
to t	he epidemiology of hyperto	ension, you should declare	all relationships with manufacturers of antihypertens	ive
med	dication, even if that medic	ation is not mentioned in t	he manuscript.	
In it	em #1 below, report all su	pport for the work reported	d in this manuscript without time limit. For all other i	tems,
the	time frame for disclosure i	s the past 36 months.	·	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	planning of the work	
	All support for the present	None		
	manuscript (e.g., funding,			
	provision of study			
	materials, medical writing,			
	article processing charges,			
	etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
<u> </u>	Grants or contracts from	√None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	None		
	Consulting for	√ None		
ŀ	Consulting fees	None		
	Dayment or honoraria for	√ None		
)	Payment or honoraria for lectures, presentations,	None		
	speakers bureaus,			
	manuscript writing or			
	educational events			

6

Payment for expert

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

You Mar ade Mar In the relation to the relatio	nocarcinoma nuscript number (if known) ne interest of transparence related to the content of your ties whose interests may be ransparency and does not be tionship/activity/interest, if following questions apply nuscript only. author's relationships/act the epidemiology of hypertones.	ey, we ask you to disclose our manuscript. "Related" re affected by the content onecessarily indicate a biast is preferable that you do sto the author's relationship ivities/interests should be	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	•		d in this manuscript without time limit. For all other items
tne	time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from	Time frame: past √None	36 months
2	any entity (if not indicated in item #1 above).	Vivorie	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	

6

Payment for expert

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

	e: 2021-10-23		
	r <u>Name:_Li Qi</u>		
		n of ubiquitinated substrat	te proteins and their gene expression patterns in lung
	nocarcinoma		<u> </u>
	nuscript number (if known)		
rela	ted to the content of your r	nanuscript. "Related" mea	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third parties inuscript. Disclosure represents a commitment
			. If you are in doubt about whether to list a relationship/
	vity/interest, it is preferable		
	•	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
	nuscript only.		
to t	he epidemiology of hyperto	•	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
			d in this manuscript without time limit. For all other items
	time frame for disclosure i	•	u in this manuscript without time limit. For all other items
tne	time frame for disclosure i	Name all entities with	Specifications/Comments
		whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
_	manuscript (e.g., funding,		
	provision of study		
	materials, medical writing,		
	article processing charges,		
	etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
·	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	_√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
5	Payment for expert	_√None	

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

Mai ade Mai	Ir Name: Wang Jun			
<u>ade</u> Mai	nuecrint litie: Identificatio	us af objective start and a color to the	a must imp and their many assessed to the state of the st	
Mai	enocarcinoma	on of ubiquitinated substrat	e proteins and their gene expression patterns in lung	
	enocarcinoma nuscript number (if known)			
			relationships/activities/interests listed below that are	
			ns any relation with for-profit or not-for-profit third	
			f the manuscript. Disclosure represents a commitment	
			. If you are in doubt about whether to list a relationship	,
acti	ivity/interest, it is preferable	e that you do so.		
		to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
	nuscript only.			
	•	•	defined broadly. For example, if your manuscript pertai	
		· •	all relationships with manufacturers of antihypertensive	9
	dication, even if that medic		•	
	· · · · ·		d in this manuscript without time limit. For all other ite	ms,
tne	time frame for disclosure i			
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)	
		none (add rows as	institution)	
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	None	pranting of the north	
_	manuscript (e.g., funding,	None		
	provision of study			
	materials, medical writing,			
	article processing charges,			
	etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	√None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	None		
	Consulting fees	None		
4				
4		1		
4	Payment or honoraria for	None		
	lectures, presentations,	None		
		None		
	Consulting fees	None		

6

Payment for expert

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

Date	e: 2021-10-23			
You	r Name:_Peng Bo			
Mar	nuscript Title:_ Identification	on of ubiquitinated substrat	e proteins and their gene expression patterns in lung	•
	nocarcinoma		<u></u>	
	nuscript number (if known)			
to ti	ne content of your manusc	ript. "Related" means any r	relationships/activities/interests listed below that are relation with for-profit or not-for-profit third	
			f the manuscript. Disclosure represents a commitmer	
	ransparency and does not vity/interest, it is preferable		If you are in doubt about whether to list a relationsh	ip/
	following questions apply nuscript only.	to the author's relationship	ps/activities/interests as they relate to the <u>current</u>	
The	author's relationships/act	ivities/interests should be	<u>defined broadly</u> . For example, if your manuscript pert	ains
		-	all relationships with manufacturers of antihypertens	
		cation is not mentioned in t	· · · · · · · · · · · · · · · · · · ·	
			d in this manuscript without time limit. For all other i	tems.
	time frame for disclosure i	• •		,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	,	
		needed)		
		Time frame: Since the initial	planning of the work	
	All support for the present	None		
-	manuscript (e.g., funding,			
	provision of study			
	materials, medical writing,			
	article processing charges,			
	etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	√None		
	any entity (if not indicated			
	in item #1 above).			
}	Royalties or licenses	None		
ļ	Consulting fees	None		
5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			

Payment for expert

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

<u>D</u> ate	e: 2021-10-23			
	r Name:_Liu Jian			
Mar	nuscript Title:_ <u>Identificatio</u>	on of ubiquitinated substra	te proteins and their gene expression patterns in lung	
<u>ade</u>	nocarcinoma		<u></u>	
In th		, we ask you to disclose all	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third	
part to to	ties whose interests may be	e affected by the content o necessarily indicate a bias	f the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a relationship/	
	following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current	
The	author's relationships/act	ivities/interests should be	defined broadly. For example, if your manuscript pertains	5
med	dication, even if that medic	cation is not mentioned in t	•	
	· •		d in this manuscript without time limit. For all other item	s,
the	time frame for disclosure i	s the past 36 months.		
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	planning of the work	
1	All support for the present	None		
	manuscript (e.g., funding,			
	provision of study			
	materials, medical writing,			
	article processing charges,			
	etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	√None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	None		
4	Consulting fees	None		
5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			

_None

6

Payment for expert

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

		ICIVIJE DISCL	OSURE FURIVI	
<u>Dat</u>	<u>:e:</u> 21-10-23			
	ır <u>Name:_Zhang Pengfe</u>			
		ation of ubiquitinated su	<u>ubstrate proteins and their gene expression pat</u>	<u>terns in</u>
	g adenocarcinoma			
	nuscript number (if kno			
	-	• •	ose all relationships/activities/interests listed b	
			ated" means any relation with for-profit or not-f	
			e content of the manuscript. Disclosure repres	
			arily indicate a bias. If you are in doubt about w	hether to
		nceires a jutiner presion audient	bទ/ayប់ប់ដែន /sio terests as they relate to the <u>current</u>	
	nuscript only.	::.:	defined broadly. For everyla if your many wint went	
			defined broadly. For example, if your manuscript pert all relationships with manufacturers of antihypertens	
		cation, you should declare		live
	<u>-</u>		d in this manuscript without time limit. For all other i	toms
	time frame for disclosure i	• • • • • • • • • • • • • • • • • • • •	a in this manuscript without time innit. For an other i	terris,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
1		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	None		
	manuscript (e.g., funding,			
	provision of study materials, medical writing,			
	article processing charges,			
	etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	√None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	None		

4

5

6

Consulting fees

Payment or honoraria for

lectures, presentations, speakers bureaus, manuscript writing or educational events

Payment for expert

_None

_None

_None

✓

	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
	F 0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above c	onflict of interest in the fo	llowing box:

All authors have no conflicts of interest

Dat	e: 2021-10-23		
	r Name:_Qu Lidong		
Mar	nuscript Title:_ Identification	on of ubiquitinated substra	te proteins and their gene expression patterns in lung
ade	nocarcinoma		
Mar	nuscript number (if known)	:	
rela par to t	ted to the content of your r ties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias	I relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment if you are in doubt about whether to list a relationship/
maı	nuscript only.		ps/activities/interests as they relate to the <u>current</u>
	- · · · · · · · · · · · · · · · · · · ·		<u>defined broadly</u> . For example, if your manuscript pertains
		· •	all relationships with manufacturers of antihypertensive
	dication, even if that medic		·
	· · · · · · · · · · · · · · · · · · ·	• •	d in this manuscript without time limit. For all other items
the	time frame for disclosure i	· ·	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	Inlanning of the work
	All according to the contract	I	planning of the work
L	All support for the present	None	
	manuscript (e.g., funding, provision of study		
	materials, medical writing,		
	article processing charges,		
	etc.)		
	No time limit for this item.		
		Time frame: past	26 months
)	Grants or contracts from	√ None	- So months
_	any entity (if not indicated	- None	
	in item #1 above).		
3	Royalties or licenses	√ None	
	,		
4	Consulting fees	√ None	
	Ŭ		
	Payment or honoraria for	√ None	
5	i dyfficiit of fiorioraria for		
5	lectures, presentations,		
5	=		
5	lectures, presentations,	_	

_None

6

Payment for expert

	testimony				
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or pending	None			
	F 0				
9	Participation on a Data	√None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role in other board, society,	None			
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	✓ None			
	Stock of Stock options				
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	✓ None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

All authors have no conflicts of interest

	Date: 2021-10-23					
	Your Name: Chang Xiaoyan					
	Manuscript Title:_ Identification of ubiquitinated substrate proteins and their gene expression patterns in lung					
	adenocarcinoma					
	nuscript number (if known)		Il valationabina/activitiaa/into-sata listad balas listad			
rela par to to	ited to the content of your ties whose interests may b	manuscript. "Related" med be affected by the content of necessarily indicate a bias	Il relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmens. If you are in doubt about whether to list a relationshi	t		
maı	nuscript only.		ps/activities/interests as they relate to the <u>current</u>			
The	author's relationships/act	ivities/interests should be	<u>defined broadly</u> . For example, if your manuscript pertair	ıs		
		· •	all relationships with manufacturers of antihypertensive	;		
		cation is not mentioned in t	•			
	· · · · · · · · · · · · · · · · · · ·		d in this manuscript without time limit. For all other iter	ns,		
the	time frame for disclosure i					
		Name all entities with	Specifications/Comments			
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)			
		none (add rows as	institution			
		needed)				
		Time frame: Since the initial	planning of the work			
Ī.	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	None				
	etc.)					
	No time limit for this item.					
		Time frame: past	36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None				
3	Royalties or licenses	None				
4	Consulting fees	None				
5	Payment or honoraria for	✓ None				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or educational events					

6

Payment for expert

	testimony				
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or pending	None			
	F 0				
9	Participation on a Data	√None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role in other board, society,	None			
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	✓ None			
	Stock of Stock options				
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	✓ None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

All authors have no conflicts of interest

Date: 2021-10-23_					
Your Name:_Yao Lingqi					
Ma	Manuscript Title: Identification of ubiquitinated substrate proteins and their gene expression patterns in				
	g adenocarcinoma				
	nuscript number (if kno				
			ose all relationships/activities/interests listed b		
		-	ated" means any relation with for-profit or not-f	-	
	-	ts may be affected by th	e content of the manuscript. Disclosure repres	ents a	
	nmitment				
	-	_	a bias. If you are in doubt about whether to list	a	
		sto, this ap ntaterable thoa tlyi	ps/dctis/ties/interests as they relate to the current		
	nuscript only.			_	
		•	defined broadly. For example, if your manuscript pert		
			all relationships with manufacturers of antihypertens	sive	
	dication, even if that medic		•		
	time frame for disclosure i	•	d in this manuscript without time limit. For all other i	tems,	
tne	time frame for disclosure i	Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initial	planning of the work		
1	All support for the present	None			
	manuscript (e.g., funding,				
	provision of study				
	materials, medical writing,				
	article processing charges, etc.)				
	No time limit for this item.				
	No time minition tims item.				
		Time frame: past	26 months		
2	Grants or contracts from	✓ None	30 mondis		
_	any entity (if not indicated	- None			
	in item #1 above).				
3	Royalties or licenses	_√None			
	·				
4	Consulting fees	None			
5	Payment or honoraria for	None			
	lectures, presentations,				

manuscript writing or educational events

Payment for expert

_None

6

	testimony				
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or pending	None			
	F 0				
9	Participation on a Data	√None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role in other board, society,	None			
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	✓ None			
	Stock of Stock options				
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	✓ None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

All authors have no conflicts of interest

Date: 2021-10-23_					
Your Name:_Zhang Linyou					
Ma	Manuscript Title: Identification of ubiquitinated substrate proteins and their gene expression patterns in				
	g adenocarcinoma				
	nuscript number (if knov				
			ose all relationships/activities/interests listed b		
are	related to the content o	f your manuscript. "Rela	ated" means any relation with for-profit or not-f	or-profit	
thir	^r d				
-		y be affected by the con	ntent of the manuscript. Disclosure represents a	1	
	nmitment				
		-	pas)biansvilliey,biutaresina okouhletya bloatet uutheet <u>heerden li</u> st	а	
		st, it is preferable that yo			
		-	<u>defined broadly</u> . For example, if your manuscript per		
			all relationships with manufacturers of antihypertens	sive	
	-	ation is not mentioned in t	•		
	· •	•	d in this manuscript without time limit. For all other i	items,	
the	time frame for disclosure i		Constitution of Comments	1	
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as	nistration,		
		needed)			
		Time frame: Since the initial	planning of the work		
1	All support for the present	None			
	manuscript (e.g., funding,				
	provision of study				
	materials, medical writing,				
	article processing charges, etc.)				
	No time limit for this item.				
	No time illint for tims item.				
		Time frame: past	26 months		
2	Grants or contracts from	✓ None	30 months		
_	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	_√None			
4	Consulting fees	None			
	Daymant on have a site for	/ Name			
5	Payment or honoraria for lectures, presentations,	None			
	speakers bureaus,				

manuscript writing or educational events

Payment for expert

_None

6

		Ţ	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	_√None	
	-		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	√None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above co	onflict of interest in the following	oox:

All authors have no conflicts of interest			